Article

First Insomnia Drug for Middle-of-the-Night Waking Receives FDA Approval

Intermezzo (zolpidem tartrate sublingual tablets) has received FDA approval for use as needed to manage insomnia.

Intermezzo (zolpidem tartrate sublingual tablets) has received FDA approval for use as needed to manage insomnia characterized by middle-of-the-night waking followed by difficulty in returning to sleep. This is the first time the FDA has approved a drug for this condition.

Intermezzo should be used only when a person has at least 4 hours of bedtime remaining and should not be taken if alcohol has been consumed or with any other sleep aid, the agency noted.

Zolpidem tartrate was first approved in the United States in 1992 as the drug Ambien; Intermezzo is a lower-dose formulation of zolpidem. The recommended and maximum dose of Intermezzo is 1.75 mg for women and 3.5 mg for men, taken once per night. The recommended dose for women is lower because women clear zolpidem from the body at a lower rate than men.

As with other sleep medicines, the use of Intermezzo may cause adverse effects, including getting out of bed while not fully awake and performing an activity without knowing it or remembering having done it. The drug is a federally controlled substance because its use can be abused or lead to dependence.

Intermezzo is made by Transcept Pharmaceuticals Inc, Port Richmond, California.

Related Videos
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
© 2024 MJH Life Sciences

All rights reserved.